Reviva Pharmaceuticals Holdings, Inc. (RVPH) — 8-K Filings

8-K Filings (21)

• Reviva Pharmaceuticals Files 8-K — Apr 15, 2026 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on April 15, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). The fil
• Reviva Pharmaceuticals Files 8-K — Mar 30, 2026 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on March 30, 2026, reporting on its financial condition and results of operations. The filing includes financ
• Reviva Pharmaceuticals Files 8-K with Corporate Updates — Dec 23, 2025 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on December 23, 2025, reporting events as of December 18, 2025. The filing indicates amendments to articles o
• Reviva Pharmaceuticals Faces Delisting Notice — Oct 17, 2025 Risk: high
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on October 17, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The comp
• Reviva Pharmaceuticals Files 8-K — Sep 26, 2025 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on September 26, 2025, reporting amendments to its Articles of Incorporation or Bylaws and financial statemen
• Reviva Pharmaceuticals Files 8-K with Material Agreement Details — Sep 19, 2025 Risk: medium
  On September 18, 2025, Reviva Pharmaceuticals Holdings, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation
• Reviva Pharmaceuticals Files 8-K with Material Agreement Details — Jun 26, 2025 Risk: medium
  On June 26, 2025, Reviva Pharmaceuticals Holdings, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD di
• Reviva Pharmaceuticals Changes Auditors to EisnerAmper LLP — Jun 6, 2025 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. announced on June 3, 2025, a change in its certifying accountant. The company has dismissed its previous independent regis
• Reviva Pharmaceuticals Files 8-K — Jun 2, 2025 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on June 2, 2025, reporting on various events. The filing includes information related to Regulation FD Disclo
• Reviva Pharmaceuticals Files 8-K — May 30, 2025 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on May 30, 2025, reporting the entry into a material definitive agreement and filing financial statements and
• Reviva Pharmaceuticals Files 8-K on Financials — Mar 31, 2025 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on March 31, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure,
• Reviva Pharmaceuticals Announces Board and Officer Changes — Feb 18, 2025 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. announced on February 13, 2025, a change in its board of directors. Specifically, the company reported the departure of ce
• Reviva Pharmaceuticals Enters Material Definitive Agreement — Dec 18, 2024 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. announced on December 16, 2024, that it entered into a Material Definitive Agreement. The company also provided a Regulati
• Reviva Pharmaceuticals Files 8-K — Dec 16, 2024 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on December 16, 2024, reporting on other events and financial statements. The company, formerly Tenzing Acqui
• Reviva Pharmaceuticals Files 8-K on Corporate Actions — Dec 12, 2024 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on December 12, 2024, reporting on events that occurred on December 10, 2024. The filing indicates changes re
• Reviva Pharmaceuticals Files 8-K — Nov 12, 2024 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on November 12, 2024, reporting on other events and financial statements. The company, formerly Tenzing Acqui
• Reviva Pharmaceuticals Reports Director and Officer Changes — Sep 17, 2024 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on September 17, 2024, reporting changes effective September 15, 2024. The filing pertains to the departure o
• Reviva Pharmaceuticals Enters Material Definitive Agreement — Aug 21, 2024 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. announced on August 20, 2024, that it entered into a material definitive agreement. The company also disclosed financial s
• Reviva Pharmaceuticals Files 8-K Report — Jul 9, 2024 Risk: low
  On July 9, 2024, Reviva Pharmaceuticals Holdings, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other ev
• Reviva Pharmaceuticals Enters Material Definitive Agreement — May 29, 2024 Risk: medium
  Reviva Pharmaceuticals Holdings, Inc. announced on May 28, 2024, that it entered into a material definitive agreement. The company, formerly known as Tenzing Ac
• Reviva Pharmaceuticals Holdings, Inc. Files 8-K — May 15, 2024 Risk: low
  Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on May 15, 2024, reporting on various events. The filing includes information about the company's structure,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX